Biotech firm, Akari Therapeutics, Plc (AKTX), disclosed significant changes in its leadership structure on Wednesday, a pivotal addition being the appointment of seasoned life sciences entrepreneur, Samir Patel, as Interim Chief Executive Officer.
Effective immediately, Rachelle Jacques will be stepping down from her role as CEO, with Melissa Bradford-Klug also leaving her position as the company's Chief Operating Officer. Following Jacques' resignation, the board of directors at Akari has designated Patel as the Interim CEO. Patel has been a Board member since December 2023.
A long-standing ally and investor in Akari, Patel brings with him extensive experience in the life sciences sector, alongside a successful history with numerous startup ventures.
Currently, Patel is the founder and major operative at PranaBio Investments, LLC. He also works in an advisory role for GE Global Research, the division responsible for advancing innovative products and solutions in various sectors, including biomanufacturing and biotechnology.
Patel's career in life sciences spans over 20 years, during which he contributed to the formation of Digital Therapeutics, LLC, and SPEC Pharma, LLC. In the past, he has also undertaken multiple roles within Medical Affairs at Centocor, Inc.
